PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
▲ Peaking Health

Experimental Nose Drops Restored Fading Memory And Boosted Neuron Growth In Mice

University of Sydney researchers used nasal mRNA drops to restore memory and boost neuron growth in aged and Alzheimer's-model mice.

8sources
8articles
28velocity
+102%since first seen
1h agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

University of Sydney researchers have developed an experimental nasal spray that delivers messenger RNA encoding brain-derived neurotrophic factor (BDNF) to mice, restoring memory performance in aged animals to youthful levels and improving cognition in mice engineered with familial Alzheimer's disease mutations. The treatment uses lipid nanoparticles — similar to those in mRNA COVID-19 vaccines — to protect the mRNA cargo and enable delivery through the nasal cavity, bypassing the blood-brain barrier that blocks many neurological drugs. Functional genomicist Greg Neely, who led the study, said, "In aged mice, we saw learning and memory significantly increased, returning animal cognition to its youthful prime." The researchers treated 18-month-old mice with the mRNA drops and compared them with untreated juveniles and older animals given a control. Treated older mice performed similarly to young animals in tests assessing object recognition, working memory, and spatial memory, while their physical activity remained lower, indicating the cognitive improvement was not due to increased energy. The aging animals' hippocampi contained more cells bearing signs of newly developing neurons. In mice engineered to carry mutations associated with familial Alzheimer's disease, treatment began at two months and continued twice weekly. From four months of age, treated mice performed better than controls across memory tasks, even though their amyloid plaque burden was unchanged. Neely noted this distinction matters because supporting neurons could complement therapies that target amyloid. In laboratory cultures, BDNF production remained detectable for four days after delivery. The drops had no noticeable effect on the cognition of healthy young mice. Neely cautioned, "Human noses are different from mouse noses, so we will need to test our drugs in humans," and longer-term safety testing is needed. A separate study published this year used nasal nanoparticles carrying instructions for BDNF and anti-inflammatory proteins to improve cognition in mice with repeated mild brain injuries, suggesting nasal delivery of neurological treatments could become a common approach.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.

Quick answers

What does the nasal spray contain and how does it work?

The spray delivers messenger RNA encoding brain-derived neurotrophic factor (BDNF) inside lipid nanoparticles. The nasal drops turn cells lining the nose into temporary protein factories, increasing BDNF levels in the brain and bypassing the blood-brain barrier.

What were the results in aged mice and Alzheimer's-model mice?

Treated 18-month-old mice performed similarly to young animals on object recognition, working memory, and spatial memory tests, with more newly developing neurons in the hippocampus. Mice with familial Alzheimer's mutations treated from two months showed better memory performance from four months onward, despite unchanged amyloid plaque burden.

What are the next steps and limitations noted by the researchers?

Greg Neely said human nasal anatomy differs from mice, so human testing is needed, along with longer-term safety studies. The treatment did not improve cognition in healthy young mice, and all benefits remain in mouse models for now.

Coverage (8)

Topics

Related trends

\n \n \n \n \n \n \n